Comparative Pharmacology
Head-to-head clinical analysis: FLUOXYMESTERONE versus ORETON METHYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOXYMESTERONE versus ORETON METHYL.
FLUOXYMESTERONE vs ORETON METHYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic androgen receptor agonist; binds to androgen receptors, modulating gene expression and promoting protein synthesis, muscle growth, and secondary sexual characteristic development.
Methyltestosterone is a synthetic androgen that binds to androgen receptors, activating transcription of androgen-responsive genes, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development.
Adults: 5-20 mg orally once daily. For replacement therapy, 5-10 mg daily; for hypogonadism, 5-20 mg daily for several months.
10-50 mg orally or buccally 1-3 times daily; or 25-100 mg IM every 2-4 weeks.
None Documented
None Documented
Clinical Note
moderateAcarbose + Fluoxymesterone
"Acarbose may increase the hypoglycemic activities of Fluoxymesterone."
Clinical Note
moderateSunitinib + Fluoxymesterone
"Sunitinib may increase the hypoglycemic activities of Fluoxymesterone."
Clinical Note
moderatePrednisolone + Fluoxymesterone
"Prednisolone may increase the fluid retaining activities of Fluoxymesterone."
Clinical Note
moderateDexamethasone + Fluoxymesterone
Terminal elimination half-life: 9.2 hours; clinical context: supports once-daily dosing for androgen replacement, with steady-state achieved in ~2 days
Terminal half-life approximately 2.7–3.8 hours; brief due to rapid hepatic metabolism.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%
Primarily renal as conjugated metabolites; ~90% urinary, ~6% fecal within 4 days.
Category C
Category C
Androgen
Androgen
"Dexamethasone may increase the fluid retaining activities of Fluoxymesterone."